Long-Term Outcomes of Teplizumab for Type 1 Diabetes
This study is observing the long-term effects of teplizumab in people with Stage 2 Type 1 Diabetes (T1D). Teplizumab is a drug already being used in regular medical care. Researchers want to see how well it delays the progression to Stage 3 T1D. You could be eligible if you have Stage 2 T1D and have received at least one teplizumab infusion within the last six weeks. The study will also look at how teplizumab affects your quality of life, including emotional and social aspects. This will help us understand how the treatment works over time for many different people. The study aims to enroll 1000 participants, but its current recruitment status is unclear.
- Study design
- This is an observational study, meaning researchers will watch how teplizumab is used in real-world settings. It plans to include 1000 participants.
- What's involved
- You will be followed for up to 10 years after starting teplizumab treatment. The study will not administer any treatment, only observe the treatment as prescribed.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 10 years after starting teplizumab treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Long-Term Outcomes of Teplizumab in Routine Clinical Care
At a glance
Conditions
Where it's being run
10 sites across 5 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Time from teplizumab infusion start to the onset of Stage 3 T1DFrom start of infusion to maximum of 10 years